Compared to CA19-9, the only existing cancer marker, TAGLN2, showed a significantly higher ROC AUC in distinguishing patients with cholangiocarcinoma than those with normal or benign disease (TAGLN2 vs. CA19-9:0.901 vs. 0.799, P = 0.026), moreover, combining with CA19-9, ROC AUC was increased even 0.948. This evidence concerns the gene TAGLN2 and cholangiocarcinoma.